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EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) 
WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART 
FAILURE
Cyr PL1, Slawsky K1, Olchanski N1, Krasa H2, Zimmer C2, Ouyang J2, Goss TF3, Udelson 
J4, Hauptman PL5
1Boston Healthcare Associates, Inc., Boston, MA, USA, 2Otsuka Pharmaceutical Development 
& Commercialization, Inc., Rockville, MD, USA, 3Boston Healthcare Associates, Inc., 
Washington, DC, USA, 4Tufts Medical Center, Boston, MA, USA, 5Saint Louis University 
School of Medicine, Saint Louis, MO, USA
OBJECTIVES: Hyponatremia has been associated with increased length of stay (LOS) 
in patients hospitalized for heart failure (HF). To date, little has been reported about 
the impact of pharmacologic intervention for hyponatremia on hospital LOS in this 
patient population. We evaluated the impact of tolvaptan, a new oral non-peptide 
vasopressin antagonist versus standard of care (SOC) on the index hospitalization LOS 
in patients with HF and concomitant hyponatremia in the EVEREST (Efﬁcacy of  
Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) multina-
tional Phase 3 trial. METHODS: A post-hoc analysis of covariance (ANCOVA) was 
performed on the hyponatremic subset of EVEREST. Both bivariate and multivariate     
analyses were conducted to account for regional variation attributed to the multina-
tional study design. Separate analyses were conducted according to patients’ admission        
serum sodium (135 mEq/L and 130 mEq/L). The model was adjusted for treatment      
as a factor and both region and treatment and region interaction term as covariates. 
Signiﬁcance was assessed with student’s t-test at (p  0.05). RESULTS: In patients 
with admission serum sodium 135 mEq/L, those receiving tolvaptan (n  225) had 
an adjusted LOS 1.72 days shorter than those receiving SOC (n  216) (p  0.061). 
In more severely hyponatremic patients (130 mEq/L), tolvaptan patients (n  21) had 
an adjusted LOS 2.12 days shorter than those receiving SOC (n  48) (p  0.581). 
Although not signiﬁcant due to small cell size, these trends in reduced index hospital-
ization LOS with tolvaptan use remained consistent in both the bivariate and multi-
variate analyses. CONCLUSIONS: Use of tolvaptan in hyponatremic patients 
hospitalized for heart failure may be associated with a decrease in hospital LOS com-
pared to SOC treatment. Larger studies, particularly in severely hyponatremic HF        
populations, are necessary to conﬁrm the statistical signiﬁcance of a LOS difference 
of this magnitude.
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LOADING WITH WARFARIN PROLONGS LENGTH OF HOSPITAL STAY 
IN PATIENTS WITH ATRIAL FIBRILLATION
Tan ES, Brown SH, Bonnett TJ, Abdelhaﬁz AH
Rotherham General Hospital, Rotherham, UK
OBJECTIVES: The goal of this study was to determine whether initiation of warfarin 
treatment in patients with atrial ﬁbrillation (AF), while in hospital, is associated with 
increased length of stay. METHODS: This was a prospective study involving patients 
with AF newly started on warfarin while in hospital. It was conducted in 3 acute 
medical wards (total 96 beds) of a district general hospital. Patients were reviewed 
daily regarding the necessity of their hospital stay. Their stay was considered delayed 
if their original medical condition had resolved and their stay was attributed solely to 
initiation of warfarin to reach a therapeutic International Normalized Ratio (INR). 
The Barthel Index score was used to assess patients’ activities of daily living. The 
medical teams treating these patients were unaware of the objective of the study. 
RESULTS: Over a 6-month period 23 patients with AF (13 men, 10 women; mean 
[SD] age, 75.4 [9.2] years) were started on warfarin while in hospital and thus com-
prised our study group. Of these 23 patients, 7 (30%) had delayed discharges that 
were solely attributed to initiation of warfarin. Total length of stay for all patients 
combined was 217 days; of these, 36 (17%) days were considered delayed discharges. 
Only 10 (43%) patients were discharged with their INR in the target range of 2 to 3. 
There was no signiﬁcant difference between patients who had delayed discharges 
versus non delayed discharges in terms of age, sex, number of comorbidities, number 
of medications, Barthel Index score, reason for admission, mean INR, number of 
patients achieving target INR on discharge, or warfarin loading regimens. CONCLU-
SIONS: Initiation of warfarin in these patients with AF while in the hospital led to 
increased length of stay. A move toward starting anticoagulation in an outpatient 
setting could reduce length of hospital stay.
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METHODOLOGY TO ASSESS THE IMPACT OF POOR COMPLIANCE 
WITH COMMON TREATMENTS
Meszaros A, Truman P
University of York, York, UK
OBJECTIVES: Poor-compliance with medicines is commonly recognised amongst 
health care practitioners, and is associated with economic and health consequences. 
By not using prescribed medicines optimally, patients are essentially wasting health 
service resources that could be put to effective use elsewhere. Our aim was to evaluate 
the economic/patient impact arising from poor compliance with commonly used 
medications. Economic models were developed for several studies to examine the 
impact of non-compliance on patient outcomes and health care resource consumption 
within the NHS. METHODS: Case studies included hypertension, high cholesterol/
coronary heart disease, and diabetes. The selection of case studies considered, condi-
tions which are treated with high volumes of low and high cost drugs and the signiﬁ-
cant volume of unused medicines was reported. For each of the studies a decisin 
analytic model was developed, intending to reﬂect the treatment pathways and patient 
outcomes associated with treatment. Event rates for relevant endpoints were derived 
from clinical trial evidence. For the events considered, cost was derived from published 
literature. Treatment costs were calculated using unit costs from the British National 
Formulary; in case of multiple therapeutic options, treatment cost was based on the 
most widely used intervention, or the intervention on which event rates were based. 
Utility values for patients were also derived from the literature to allow estimates of 
the loss of quality of life of individuals. RESULTS: Diabetes (compliance vs. partial 
noncompliance): £128.35, 0.02; Hypertension (compliance vs. partial compliance): 
£121.70, 0.03; Hypertension (compliance vs. non compliance): £167.85, 0.06; 
Hypercholesterolemia (compliance vs. partial compliance): £133.18, 0.04; Hypercho-
lesterolemia (compliance vs. non compliance): £135.73, 0.05 for incremental costs 
(per-patient), incremental utilities (per-patient). CONCLUSIONS: The results conﬁrm 
that resources are wasted and there is signiﬁcant loss in quality of life with partial 
(non)compliance. It is hoped that the approaches developed in this research might be 
suitable for further development and application to a wider range of conditions.
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COMPLIANCE (ADHERENCE) TO ANTIHYPERTENSIVE THERAPY  
IN AUSTRALIA
Ortiz M1, Calcino G2
1Solvay Pharmaceuticals Australia, Pymble, NSW, Australia, 2Hi Connections Pty Ltd, Woden, 
ACT, Australia
OBJECTIVES: To compare different methods of assessing adherence to antihyperten-
sive (AHT) therapy, since some methods may be confounded by differences in persis-
tence. METHODS: Australian Pharmaceutical Beneﬁts Scheme (PBS) claims data 
provided by Medicare Australia has been used to assess compliance to AHT therapy. 
This analysis is based on all scripts supplied to a one in ten sample of the Australian 
patient population drawn from de-identiﬁed PBS payment records from June 2003 to 
June 2005. PBS prescriptions for most AHT products are for 28 or 30 days supply. 
Concessional patients newly initiated to; dihydropyridine (DHP) Calcium Channel 
Blockers (CCB), angiotensin two receptor antagonists (A2RA) and angiotensin con-
verting enzyme inhibitors (ACE), were identiﬁed and the following compliance infor-
mation determined: number of scripts dispensed in the 12 months post initiation; 
average time between reﬁlls; median medication possession ratio (MPR) and median 
persistence. RESULTS: More than 85,000 Australian Concessional patients were initi-
ated on these AHT products. Assessment of compliance (adherence) found the interval 
between reﬁlls for AHTs was 34 days or less for 75% of patients and median MPRs 
exceeded 90% (considered compliant), yet the mean number of scripts collected in 
365 days was only 8.0 per patient (considered non compliant) There were large dif-
ferences between AHT products. Mean intervals between reﬁlls ranged from 28 
(trandolapril) to 44 (captopril) days, while average scripts per patient per year ranged 
from 3.8 (captopril) to 8.8 (lercanidipine). Median persistence to the molecule ranged 
from 2 months (captopril) to 19 months (lercanidipine). CONCLUSIONS: Using 
scripts counts over a year period to assess patient compliance may be misleading. 
Intervals between reﬁlls suggest that most patients are compliant if they collect their 
prescriptions.
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NONADHERENCE AND DISCONTINUATION OF LOW-DOSE 
ACETYLSALICYLIC ACID IN PATIENTS WITH CARDIOVASCULAR RISK: 
THE IMPACT OF GASTROINTESTINAL SYMPTOMS
Sörstadius E1, Thompson VJ2, Pratt SE3, Delgado JP4, Elkin E5, Nauclér E1, Næsdal J1, 
Junghard O1
1AstraZeneca R&D, Mölndal, Sweden, 2Libra Clinical Research Associates LLC, Brick, NJ, 
USA, 3Harmony Clinical Research, San Ramon, CA, USA, 4Integrated Medical Research, 
Ashland, OR, USA, 5ICON Clinical Research, San Francisco, CA, USA
OBJECTIVES: To characterise the effect of upper gastrointestinal (GI) symptoms on 
nonadherence and discontinuation of low-dose acetylsalicylic acid (ASA; aspirin) in 
patients with cardiovascular (CV) risk. METHODS: This observational study (Clini-
calTrials.gov identiﬁer: NCT00681759; AstraZeneca study code: D961FC00004), 
conducted at 77 centres in USA, Canada and France, included patients q18 years at 
risk of or with CV disease, about to begin or previously prescribed daily low-dose 
ASA (75–325 mg) within 5 years. Nonadherence (75% of low-dose ASA taken) and 
discontinuation (no low-dose ASA use for 7 continuous days) were assessed using 3 
months prospective data collected by eDiary q3 times/day. RESULTS: 340 patients 
(mean age 50 years; 59% women) were assessed; 65% needed low-dose ASA for sec-
ondary or high-risk primary CV prevention, and 35% for lower-risk primary preven-
tion. Most (75%) were low-dose ASA-naïve at inclusion, with no upper GI symptoms 
within the previous 14 days. Overall, 18% of patients were nonadherent. Adherence 
was negatively inﬂuenced by upper GI (odds ratio [OR] 0.84; 95% CI 0.70, 1.00; 
p  .05) and dyspeptic (OR 0.81; 95% CI 0.66, 1.00; p  0.05) symptoms. Low-dose 
ASA-naïve patients at inclusion had the greatest risk of nonadherence associated with 
upper GI episodes (OR 0.76; 95% CI 0.57, 1.00; p  0.05). Overall, 13% of patients 
discontinued low-dose ASA therapy. Upper GI symptoms were associated with an 
increased risk of discontinuation (hazard ratio [HR] 1.1; 95% CI 1.0, 1.2; p  0.01). 
Discontinuation risk increased with more frequent upper GI symptoms, overall and 
in low-dose ASA-naïve patients. Among the latter, patients experiencing GI symptoms 
q 3 times during the preceding week had       7 times the risk of discontinuation than 
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patients with no episodes (HR 7.5; 95% CI 2.6, 22.0; p  0.01). CONCLUSIONS: 
Upper GI symptoms were signiﬁcantly associated with poor adherence to and discon-
tinuation of low-dose ASA. Strategies to help patients continue with low-dose ASA 
cardioprotection are warranted.
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DIFFERENCES IN PERSISTENCE BETWEEN CCBS WHEN COMBINED 
WITH AN A2RA OR AN ACE ANTIHYPERTENSIVE IN AUSTRALIA
Ortiz M1, Calcino G2
1Solvay Pharmaceuticals Australia, Pymble, NSW, Australia, 2Hi Connections Pty Ltd, Woden, 
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OBJECTIVES: To assess persistence to the combinations of dihydropyridine (DHP) 
calcium channel blockers (CCB) with an Angiotension Converting Enzyme (ACE) 
inhibitors or an Angiotension II Receptor Antagonist (A2RA), using PBS claims data 
provided by Medicare Australia. METHODS: This analysis is based on all scripts 
supplied to a one in ten sample of the Australian population drawn from de-identiﬁed 
Pharmaceutical Beneﬁts payment records from January 2003 to December 2006. Ini-
tiation occurred with 2 consecutive months of an A2RA or an ACE combined with a 
DHP following at least 6 months without a DHP combination. Treatment cessation 
was 3 consecutive months of none or just one of the drugs making up the combination. 
Hazard ratios (HR) were derived and adjusted for patient age/ sex and initiating 
 speciality. RESULTS: More than 17,500 Concessional patients, initiated on a DHP 
combined with an A2RA and more than 12,000 Concessional patients, initiated on a 
DHP combined with an ACE, had their persistence to the combination assessed. 
Median persistence [95% CI] differed between DHP combinations: Lercanidipine/
A2RA 23 months [22–25], Felodipine/A2RA 20 months [18–22], Nifedipine/A2RA 
17 months [16–18], and Amlodipine/A2RA 14 months [13–15]. Using Lercanidipine/
A2RA as the reference (HR  1.00), patients were signiﬁcantly more likely to cease 
the other combinations Felodipine/A2RA (8.7%), Nifedipine/A2RA (18.5%) and 
Amlodipine/A2RA (33.9%). Lercanidipine/ACE 24 months [22–26], felodipine/ACE 
21 months [19–24], nifedipine/ACE 16 months [14–18], and amlodipine/ACE 15 
months [14–17]. Using Lercanidipine/ACE as the reference (HR  1.00), patients were 
more likely to cease the other combinations felodipine/ACE (7.2%), nifedipine/ACE 
(26.5%) and amlodipine/ACE (28.6%). CONCLUSIONS: In terms of optimal treat-
ment persistence, lercanidipine seems to be the best DHP to combine with an A2RA 
or an ACE, while amlodipine seems to be the worst DHP to combine with an A2RA 
or an ACE.
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INFLUENCING FACTORS TO A GOOD ADHERENCE IN PATIENTS WITH 
CHRONIC HEART DISEASES
Origasa H, Sugiura S, Kumagai N, Sumi S
University of Toyama School of Medicine, Toyama, Japan
OBJECTIVES: To identify enhancing factors of the medication adherence using the 
data from a randomized trial of patients with chronic heart diseases. METHODS: We 
used the data from a randomized trial involving a total of 6967 patients with chronic 
heart diseases. This trial followed up them with an average of 5 years. Adherence rate 
was obtained by the division of a number of days to take a targeted medicine by 365 
days each year for each patient. The targeted medicine was the one assigned by ran-
domization. An overall adherence rate for each patient was deﬁned by an average of 
annual adherence rates during the follow-up period. Good medication adherence was 
deﬁned by the overall adherence rate of 80% or more. An adjusted odds ratio (OR) 
was used to show the degree of inﬂuence to a good adherence. RESULTS: Very high 
rate (94%) of good adherence was observed since the medication was an assigned 
drug in a randomized trial. Enhancing the odds of good adherence was women (OR 
 1.13, P  0.007), age (OR per 5-year increase  2.33, P  0.17), patients taking 5 
or more medicines (OR  1.45, P  0.001), and good status on diet therapy (OR  
1.95, P  0.001). Conversely, smokers decreased the adherence by 12% (P  0.008) 
and patients with previous stroke decreased the adherence by 29% (P  0.001). 
CONCLUSIONS: Patients taking many drugs or receiving diet therapy and women 
showed a statistically signiﬁcant increase in the medication adherence.
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PREDICTORS OF NON-PERSISTENCE ON STATIN TREATMENTS IN 
ITALY: A RETROSPECTIVE
Cammarota S1, de Portu S2, Riegler S3, Citarella A1, Menditto E1, Mantovani LG3
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OBJECTIVES: The aim of this study was to estimate predictors of non-persistence 
with different statin treatments by the analysis of a general practitioner’s (GP’s) data-
base covered a population of 144,000 inhabitants. METHODS: We analysed a cohort 
of adult patients (35 years) who newly initiated statin therapy between January 
1,2005 and December 31,2005. The initiator status was conﬁrmed by the absence of 
any statin prescription within 365 days prior to statin initiation. Persistence of statin 
utilization was analysed over 3 years follow-up period. The period covered by a pre-
scription was deﬁned by the number of tablets dispensed, based on one tablets per 
day. Treatment was considered discontinued if the interval between two prescriptions 
exceeded number of tablets prescribed, plus 60 days. Persistence was deﬁned as the 
period from the ﬁrst prescription date to the date of discontinuation. A Kaplan-Meier 
survival analysis and a multivariate Cox proportional hazards regression analysis was 
performed including in the model all covarietes (demographic characteristics, comor-
bilities, previous therapies) that may potentially confound the association between 
cohort and outcome. RESULTS: The ﬁnal sample included 2382 patients (28.4% 
simvastatin; 7.3% ﬂuvastatin; 13.4% pravastatin; 30.7% atorvastatin; 20.3% rosuv-
astatin). Only 23.2% of patients persisted for 3 years of therapy. Female gender and 
absence of diabetes comorbidity were the most signiﬁcant predictors of early discon-
tinuation. CONCLUSIONS: Further studies are required to evaluate whether these 
factors are related to persistence to treatment.     
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HEALTH STATUS IN AN ARGENTINIAN POPULATION  
SURVEY : RESULTS FROM THE NATIONAL RISK FACTOR SURVEY
Augustovski FA1, Irazola V1, Kind P2
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OBJECTIVES: To describe general population self-reported EQ-5D-VAS (VAS) and 
to explore its univariate relationships with sociodemographic (SDC) and health char-
acteristics. METHODS: In 2005, the ﬁrst “Risk Factors National Survey” was under-
taken in Argentina, including 41,392 adults randomly selected from all Argentine 
provinces. Data were obtained on SDC, risk factors, and health status (EQ-5D and 
the general health question of SF-36). Mean and CI95% or median (IQR) are reported. 
All signiﬁcant differences had p values 0.01. RESULTS: VAS had a mean of 75.35 
(74.94 75.75) and a median of 80 (70–90). General population mean and median 
social TTO based weights were 0.902 (0.898–0.905) and 1 (0.88–1). The range of 
reported limitations in each of the EQ-5D domains ranged from 2.9% in self-care to 
30.9% in pain/discomfort. 44.9% had at least some limitation in one of the EQ-5D 
states, and 19.9% had a self-reported fair or poor health. VAS had a correlation of 
0,49 with TTO based social weights. General Health was strongly correlated to VAS: 
those with excellent health had a mean of 91.76, while those with poor health had a 
mean of 39.43. Subjects that reported having a health problem in the last month had 
signiﬁcantly less VAS than those who did not: 70.66 vs. 80.39. VAS was signiﬁcantly 
related to cardiovascular risks factors (high blood pressure, high-cholesterol, over-
weight, high glycemia, low physical activity) except smoking. VAS was signiﬁcantly 
lower in females, in the elderly, in subjects with less education, lower household 
income, and unemployed. CONCLUSIONS: VAS showed expected relations with 
SDC variables, with General Health, and in general, it showed to behave as expected 
with the presence of cardiovascular risk factors with the exception of smoking. This 
is one of the few general population surveys in Latin America that incorporated the 
EQ-5D tool to describe population health status.
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HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND 
ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS
Doyle S1, Lloyd A2, Craig AM3
1Oxford Outcomes, Oxford, Oxon, UK, 2Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 
3Sanoﬁ Aventis, Guildford, Surrey, UK
OBJECTIVES: The study aimed to describe common adverse events associated with 
atrial ﬁbrillation medications, as well as atrial ﬁbrillation (AF) itself. The AF and 
adverse event descriptions were used to estimate societal utility values in the UK. 
METHODS: AF base health state descriptions were produced based on EQ-5D survey 
data with input from patients and clinicians. Adverse event descriptions were bolted 
to the EQ-5D derived base AF health states so that the associated disutility of speciﬁc 
treatment adverse events could be described. The health states described both parox-
ysmal/persistent and permanent AF along with 14 adverse events. Interviews with ﬁve 
AF experienced clinicians and six AF patients were carried out to assess the content 
and face validity of the health states. In total, 127 members of the UK general public 
valued the health states in a time trade-off (TTO) interview and ranking task. 
RESULTS: The study revealed the public preferences for atrial ﬁbrillation and associ-
ated adverse event health states. There was a range of disutility reported for the 
adverse events from 0.01 for dizziness, 0.03 for rash, 0.08 for diarrhoea, 0.10 
for hypothyroidism, to 0.17 for pulmonary complications. CONCLUSIONS: The 
study provides insight into the importance of atrial ﬁbrillation treatment adverse 
events on patient’s quality of life. As atrial ﬁbrillation is a largely asymptomatic condi-
tion, the impacts of treatment adverse events on health related quality of life are 
amongst the most important factors considered in treatment decisions. The utility 
values collected in this study may prove useful in populating cost-effectiveness 
analyses.
PCV137
PREFERENCES OF PATIENTS, PHYSICIANS AND CAREGIVERS IN THE 
CHOICE OF ABDOMINAL AORTIC ANEURYSMS TREATMENT OPTIONS: 
THE PREFER STUDY
Scalone L1, Borghetti F2, Faggioli G3, Stella A3, Cortesi P2, Mantovani LG4
1University of Milan—Bicocca, Milan, Italy, 2University of Milan, Milan, Italy, 3Sant’Orsola 
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Naples, Italy
OBJECTIVES: Factors inﬂuencing preferences towards type of abdominal aortic aneu-
rysm (AAA) have been scarcely investigated. The objective was to identify character-
istics important for physicians, patients and their caregivers in the treatment of AAA. 
METHODS: We conducted a Discrete Choice Study involving AAA patients, their 
caregivers and experienced vascular surgeons. Participants self-completed question-
naires including 4–8 choice sets comparing pairs of options obtained from a factorial 
combination of 6 characteristics previously selected during a focus group and pilot 
study: type of anaesthesia (general vs. local); recovery time to everyday basic activities 
